Global Hereditary angioedema
Market, by Distribution Channel
- The report estimates that in 2017, there were approximately 402,700 prevalent cases of hereditary angioedema
worldwide, and forecasts that number to increase to 440,600 prevalent cases by 2026.
Defective glycosylation of coagu lation factor XII underlies hereditary angioedema
: first report of the Brazilian registry and challenges.
Cicardi, "Pathophysiology of hereditary angioedema
," Pediatric Allergy, Immunology, and Pulmonology, vol.
Farkas, "The natural history of hereditary angioedema
and the impact of treatment with human C1-inhibitor concentrate during pregnancy: A long-term survey," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.
This study was designed to determine the prevalence and occurrence of clinical manifestations of hereditary angioedema
(HAE) in previously unevaluated blood relatives of known (index) patients with HAE in a few villages of a city in a province (Duzce) in Turkey.
Novel and recurrent mutations in the C1NH gene of Arab patients affected with hereditary angioedema
. Int Arch Allergy Immunol 2010;151(2):149-54.
Simon Estcourt, Managing Director, Managed Access, Clinigen Group said: "We are very pleased to work with Pharming to help HAEi realize their mission to ensure that sufferers of hereditary angioedema
worldwide can access this effective and potentially life-saving treatment.
Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema
. J Allergy Clin Immunol.
Medications currently used for treating acute episodes of angioedema in patients with hereditary angioedema
may be useful in the management of other types of angioedema, including ACE-inhibitor-related angioedema.
The submission includes data from two completed trials of the product for the prophylaxis of hereditary angioedema
attacks, a randomised, double-blind, placebo-controlled trial and an open-label study.
Contract notice: medicinal products used in hereditary angioedema
Additionally, because it uses the same vector, the ADVM053 program for hereditary angioedema
is now on hold with an expected update in the first half of next year, Van Buren tells investors in a research note.
M2 EQUITYBITES-November 27, 2017-Pharming Group NV submits RUCONEST BLA with US FDA for hereditary angioedema